

Alaska Medicaid

DALIRESP®(roflumilast)
Available 500mcg tablets

INDICATIONS and USAGE:

“ DALIRESP is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

Limitations of Use: DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm.”¹

- Daliresp is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C)
- Daliresp should not be used during pregnancy, labor or delivery, or by nursing mothers because excretion of roflumilast and/or its metabolites into human milk is probable.

Criteria for Approval:

1. Diagnosis of approved indication; **AND**
2. Spirometry results supporting diagnosis of severe COPD²; **AND**
 - a. $FEV_1/FVC < 0.70$ **OR**
 - b. $FEV_1 < 50\%$ predicted on post-bronchodilator FEV_1
3. Current therapy with Long-acting bronchodilator therapy; **AND**
4. History of COPD exacerbations of two or more in the last 12 months

Length of Authorization:

1. Coverage may be approved for up to 12 months

Dispensing Limit:

1. The dispensing limit is a 30 day supply of medication with a **Quantity Limit of 1 per day.**

References:

¹ Daliresp® package insert is available at: <http://www.frx.com/pi/Daliresp_pi.pdf >
Accessed 8/31/12

² GOLD Spirometry Guide is available at:< <http://www.goldcopd.org/other-resources-gold-spirometry-guide.html> >
Accessed 9/4/12